ERYTECH Collaborates with Fox Chase Cancer Center to Advance Its Platform in the Field of Rare Metabolic Disorders
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Fox Chase Cancer Center (FCCC) to advance the pre-clinical development of the Company’s erymethionase program for homocystinuria, a rare and severe metabolic disorder of methionine metabolism. The collaboration will leverage FCCC’s world-class expertise to generate in vivo proof-of-concept data with erymethionase in a homocystinuria animal model.
Classical homocystinuria is a rare, inherited genetic disease caused by a deficiency in the enzyme Cystathionine Beta-Synthase (CBS), which is critical for methionine metabolism. Patients are unable to fully metabolize the amino acid methionine, an essential amino acid found in food, which leads to the accumulation of homocysteine and methionine in the blood and urine. High levels of these amino acids are directly linked to morbidity and mortality, often at a young age. Symptoms include severe intellectual disability, eye lens dislocation, thromboembolism, osteoporosis, and seizures.
The collaboration between ERYTECH and FCCC aims to demonstrate the potential of ERYTECH’s erymethionase to lower homocysteine and methionine in the homocystinuria mouse model (CBS-deficient mice) developed by Professor Warren Kruger’s lab at FCCC. Erymethionase is a methionine gamma-lyase (MGL, methioninase) enzyme encapsulated in red blood cells using ERYTECH’s proprietary ERYCAPS technology platform to provide effective, long-acting therapeutic activity with reduced toxicity. In addition to the homocystinuria program, ERYTECH is developing erymethionase as a product candidate targeting cancer metabolism. New preclinical data supporting the potential role of erymethionase as a treatment approach against a broad range of cancers that rely on methionine metabolism will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 1 – 5, 2017 in Washington, D.C.
Pr. Warren Kruger, PhD, Fox Chase Cancer Center, commented, “ERYTECH’s approach with erymethionase has significant potential in this disease setting because it can reduce the levels of both homocysteine and methionine in blood plasma which is critical in restoring the metabolic balance in individuals with classical homocystinuria. We look forward to working with ERYTECH to advance this preclinical program to determine its potential as a therapeutic option for homocystinuria patients.”
Dr. Alexander Scheer, PhD, Chief Scientific Officer of ERYTECH, added, “Classical homocystinuria remains a very challenging genetic disorder that the unique mechanism of action of erymethionase has the potential to directly and meaningfully impact. We are very pleased to enter this collaboration with FCCC and look forward to working closely with Dr. Kruger on this program as we accelerate the development of our technology platform to include highly specialized and rare conditions beyond oncology. This collaboration emphasizes ERYTECH’s overarching strategy to develop novel, safer therapies to address high unmet medical needs.”
About Fox Chase Cancer Center: www.foxchase.org
The Hospital of Fox Chase Cancer Center and its affiliates (collectively
“Fox Chase Cancer Center”), a member of the Temple University Health
System, is one of the leading cancer research and treatment centers in
the United States. Founded in 1904 in Philadelphia as one of the
nation’s first cancer hospitals, Fox Chase was also among the first
institutions to be designated a National Cancer Institute Comprehensive
Cancer Center in 1974. Fox Chase researchers have won the highest awards
in their fields, including two Nobel Prizes. Fox Chase physicians are
also routinely recognized in national rankings, and the Center’s nursing
program has received the Magnet recognition for excellence four
consecutive times. Today, Fox Chase conducts a broad array of nationally
competitive basic, translational, and clinical research, with special
programs in cancer prevention, detection, survivorship and community
For more information, call 1-888-FOX CHASE or (1-888-369-2427).
About ERYTECH: www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. ERYTECH plans to pursue regulatory approvals for its lead product candidate, eryaspase, also known under the trade name GRASPA®, having achieved positive efficacy and safety results from its completed Phase 2/3 pivotal clinical trial in Europe in children and adults with relapsed or refractory ALL. ERYTECH also has an ongoing Phase 1 clinical trial of eryaspase in the United States in adults with newly diagnosed ALL, and a Phase 2b clinical trial in Europe in elderly patients with newly diagnosed AML, each in combination with chemotherapy. ERYTECH believes that eryaspase also has the potential as a treatment approach in solid tumors and is conducting a Phase 2 clinical trial in Europe in patients with metastatic pancreatic cancer.
In addition to eryaspase, ERYTECH is developing two other product candidates that focus on using encapsulated enzymes to induce tumor starvation. The company is leveraging the ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme therapies beyond oncology (ERYZYME), such as the development of erymethionase in homocystinuria.
ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the U.S. under an ADR level 1 program (OTC, ticker EYRYY).
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on ERYTECH’s website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.
Chairman and CEO
CFO and COO
+33 4 78 74 44 38
The Ruth Group
Lee Roth, +1 646 536 7012
Kirsten Thomas, +1 508 280 6592
+33 1 44 71 98 52
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Meet Group Announces Closing of Lovoo Acquisition19.10.2017 20:58 | Pressemelding
The Meet Group, Inc. (NASDAQ: MEET), a public market leader in the mobile meeting space, has completed its acquisition of Lovoo GmbH. The LOVOO app is the most downloaded dating app in Germany, Switzerland, and Austria combined. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019006572/en/ The Meet Group anticipates this purchase will continue the momentum of its mission to meet the universal need for human connection through innovating, acquiring, and building the largest mobile portfolio of brands for meeting new people. The acquisition is expected to expand The Meet Group’s global footprint, increase the company’s scale and profitability, and diversify its business model by adding expertise in subscription and in-app purchasing. “LOVOO is our third strategic acquisition in the last 12 months, and
Edgewater Networks Announces SD-WAN Optimized for BroadSoft Platforms19.10.2017 20:00 | Pressemelding
Edgewater Networks, Inc., the market leader in Network Edge Orchestration, announces the upcoming availability of its SD-WAN offering targeted for Small to Medium Enterprises, a key market for service providers offering Unified Communications as a Service. Edgewater Networks’ SD-WAN solution is optimized for the BroadSoft BroadWorks® and BroadCloud® platforms and brings the benefits of this technology to the BroadSoft customer base. “As a new component of our Network Edge Orchestration platform, Edgewater Networks SD-WAN service allows BroadSoft customers to offer comprehensive end user service level agreements by ensuring that real-time communications are automatically routed to the best available Internet connection,” said Chris Kolstad, Edgewater Networks’ Vice President of Product Management. “Edgewater Networks’ SD-WAN offers a new revenue stream to service providers with a soluti
Business Wire Receives Type 2 SOC 2 Attestation Engagement Report Related to Security19.10.2017 19:20 | Pressemelding
Business Wire today announced that it has successfully completed a Type 2 SOC 2 examination of its BW Connect and HQ systems. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019006400/en/ The attestation engagement report, conducted by the independent CPA firm Schellman & Company, LLC, confirms that Business Wire has met the standards established by the American Institute of Certified Public Accountants [AICPA] Trust Services Principles related to security. BW Connect is Business Wire’s proprietary web-based order-entry system; HQ provides web-hosting services for online newsrooms, and investor relations hubs for publicly-traded companies. The examination, conducted during the review period February 1, 2017 through July 31, 2017, focused on Business Wire adherence to the Trust Service Principle/Secu
Pharnext: First-Half 201719.10.2017 17:30 | Pressemelding
Regulatory News: Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced its first-half 2017 financial results. Daniel Cohen, M.D., Ph.D. Co-Founder and CEO said of activity for the first half of 2017: "Activity in the first-half of the year was very dense; we implemented two prominent strategic partnerships with the biotech company Galapagos and the Tasly Group, one of the top ten pharmaceutical companies in China. Our flagship product, PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A, is nearing the end of Phase 3, which is slated for the second half of 2018. We confirm our target of taking the product to market by 2019." A half-year marked by strategic agreements
Tickets Now on Sale for FEI World Equestrian Games Tryon 2018, North Carolina, USA, on September 11-23, 201819.10.2017 16:58 | Pressemelding
Tickets for the FEI World Equestrian GamesTM Tryon 2018 (WEG) are now on sale to the public online at www.tryon2018.com. With more than 500,000 people expected to attend the 2018 Games, the 12-day spectacle of equestrian champions is one of the biggest events on the global sporting calendar and will be the largest equestrian event in North Carolina’s history. Mark Bellissimo, CEO of host venue Tryon International Equestrian Center (TIEC) in Tryon, NC, USA, said: “Demand from the event is way beyond our expectations and it would not surprise me if this event were to sell out early. We have experienced unprecedented demand, far bigger than we ever anticipated. There is tremendous appetite for this event, so we encourage people to buy now.” Tickets for the WEG include the following options: a standard Day Pass, Individual Event Pass, All Session Discipline Pas
SFL – Third-Quarter 2017 Financial Information19.10.2017 16:30 | Pressemelding
Regulatory News: SFL (Paris:FLY): Rental income: €147.8 million, up 3.3% like-for-like Consolidated revenue by business segment (€000’s) 2017 (9 months) 2016 (9 months)
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom